» Articles » PMID: 27022283

Circulating Interleukin-10 Levels and Human Papilloma Virus and Epstein-Barr Virus-associated Cancers: Evidence from a Mendelian Randomization Meta-analysis Based on 11,170 Subjects

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2016 Mar 30
PMID 27022283
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have showed interleukin 10 (IL-10) is a critical cytokine that determines antiviral immune response and is related to virus-associated cancers. However, whether genetically elevated circulating IL-10 levels are associated with the risk of human papilloma virus and Epstein-Barr virus-associated cancers (HEACs) is still unclear. Mendelian randomization method was implemented to meta-analyze available observational studies by employing IL-10 three variants (-592C>A, -819C>T, and -1082A>G) as instruments. A total of 24 articles encompassing 11,170 subjects were ultimately eligible for the meta-analysis. Overall, there was a significant association between IL-10 promoter variant -1082A>G and HEACs under allelic and dominant models (both P<0.01). Subgroup analysis by cancer type indicated that the risk estimate of -1082A>G was significant for nasopharyngeal cancer under allelic, homozygous genotypic and dominant models (all P<0.001). Moreover by ethnicity, carriers of -1082G allele had a 74% increased risk for nasopharyngeal cancer in Asians under dominant model (odds ratio [OR] =1.737; 95% confidence interval [CI]: 1.280-2.358; P<0.001). In further Mendelian randomization analysis, the predicted OR for 10 pg/mL increment in IL-10 levels was 1.14 (95% CI: 1.01-16.99) in HEACs. Our findings provided strong evidence for a critical role of genetically elevated circulating IL-10 levels in the development of HEACs, especially in Asian population and for nasopharyngeal cancer.

Citing Articles

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.

Yarmolinsky J, Robinson J, Mariosa D, Karhunen V, Huang J, Dimou N medRxiv. 2023; .

PMID: 37205426 PMC: 10187459. DOI: 10.1101/2023.05.04.23289196.


Systematic review of Mendelian randomization studies on risk of cancer.

Markozannes G, Kanellopoulou A, Dimopoulou O, Kosmidis D, Zhang X, Wang L BMC Med. 2022; 20(1):41.

PMID: 35105367 PMC: 8809022. DOI: 10.1186/s12916-022-02246-y.


Interleukin-18 and -10 may be associated with lymph node metastasis in breast cancer.

Ma T, Kong M Oncol Lett. 2021; 21(4):253.

PMID: 33664817 PMC: 7882877. DOI: 10.3892/ol.2021.12515.


Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor β on cancer cells.

Kwasniak K, Czarnik-Kwasniak J, Maziarz A, Aebisher D, Zielinska K, Karczmarek-Borowska B Cent Eur J Immunol. 2019; 44(2):190-200.

PMID: 31530989 PMC: 6745546. DOI: 10.5114/ceji.2018.76273.


Mendelian randomization studies of cancer risk: a literature review.

Pierce B, Kraft P, Zhang C Curr Epidemiol Rep. 2018; 5(2):184-196.

PMID: 30034993 PMC: 6053056. DOI: 10.1007/s40471-018-0144-1.

References
1.
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D . Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6):607-15. DOI: 10.1016/S1470-2045(12)70137-7. View

2.
Minnicelli C, Barros M, Klumb C, Romano S, Zalcberg I, Hassan R . Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS One. 2012; 7(9):e46005. PMC: 3459931. DOI: 10.1371/journal.pone.0046005. View

3.
Niu W, Liu Y, Qi Y, Wu Z, Zhu D, Jin W . Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012; 157(2):243-52. DOI: 10.1016/j.ijcard.2011.12.098. View

4.
Roh J, Kim M, Seo S, Kim S, Kim J, Park N . Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002; 184(1):57-63. DOI: 10.1016/s0304-3835(02)00193-3. View

5.
Hariri S, Unger E, Sternberg M, Dunne E, Swan D, Patel S . Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011; 204(4):566-73. DOI: 10.1093/infdis/jir341. View